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Abstract  
BACKGROUND: Successful hematopoietic stem cell transplantation (HSCT) requires a rapid and durable 
hematopoietic recovery.  
AIM: The aim of our study was to analyse factors that influence hematopoietic recovery after autologous HSCT.  
MATERIALS AND METHODS: Multiple regression analysis was used to analyse factors affecting neutrophil and 
platelet engraftment in 90 autologous transplanted patients – 30 with acute myeloid leukaemia (AML), 30 with 
lymphoma and 30 with multiple myeloma (MM) from 2008 till 2016.  
RESULTS: The neutrophil recovery in AML patients was significantly influenced by transfusion support with 
random-donor platelets, sex and number of transplanted mononuclear cells (MNC) and CD34+ cells; and in 
lymphoma patients, it was influenced by sex, age, mobilisation strategy and some transplanted MNC. The 
influence of investigated factors on neutrophil engraftment in MM patients was not statistically significant. The 
platelet recovery in AML patients was influenced by transfusion support with random-donor platelets; in lymphoma 
patients, it was influenced by sex, age, time from diagnosis to harvesting and time from diagnosis to HSCT; and in 
MM patients it was influenced by transfusion support with random-donor platelets. 
CONCLUSION: Additional studies are necessary to better understanding of engraftment kinetic to improve the 
safety of HSCT and to minimise potential complications and expenses related to HSCT. 
 
 
 
 
 
Introduction 
 
Hematopoietic stem cell transplantation 
(HSCT) is an established treatment for patients with 
life- threatening haematological and non-hematological 
diseases, including acute and chronic leukaemias, 
myelodysplastic syndromes, lymphomas, multiple 
myeloma, aplastic anaemia, immune disorders, and 
congenital disorders of metabolism [1-6]. This therapy 
consists of the intravenous infusion of hematopoietic 
progenitor cells to reestablish marrow function in 
patients with damaged or defective bone marrow [7]. 
Transplantation of hematopoietic stem cells (HSC) 
provides complete and long-term reconstitution of the 
hematopoietic system of the patients [8, 9] and may 
result in remission or cure in a proportion of cases [1]. 
Given the numerous advantages such as, lower rates 
of morbidity and mortality, shorter hospitalization, 
lower costs of treatment and the possibility of applying 
high-dose chemotherapy to an older group of patients, 
mobilized peripheral blood stem cells have largely 
replaced the use of bone marrow-derived stem cells 
as the preferred source of hematopoietic stem cells in 
autologous transplantation [7-15].  
Furthermore, the use of granulocyte- colony-
stimulating factor (G-CSF) mobilized peripheral blood 
stem cell transplantation instead of bone marrow, may 
reduce the rates of graft rejection, enhanced 
engraftment and accelerated hematopoietic recovery 
[7, 16]; because peripheral blood stem cell 
transplantation affords about 10-fold more T cells [7, 
17), compared to bone marrow, and a 2-fold higher 
CD34+ cell dose [7, 18, 19]. Fast and durable 
hematopoietic recovery with absolute neutrophil 
count (ANC) > 0.5x10
9
/l and platelets (Plt) > 20x10
9
/l 
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after reconstitution is an imperative for successful 
hematopoietic stem cell transplantation. Rapid 
hematopoietic recovery at autologous peripheral stem 
cell transplantation is a significant factor in the 
reduction of early transplant related complications and 
costs [20]. It is very important to recognise the factors 
that influence the hematopoietic recovery after 
peripheral blood stem cell transplantation.  
The aim of our study is to analyse factors that 
influence the quality of graft through hematopoietic 
recovery in autologous transplanted patients with 
peripheral blood hematopoietic stem cells. 
 
 
Materials and Methods 
 
This is a retrospective-prospective study 
performed at the Institute for Transfusion Medicine of 
RM and University Clinic of Hematology in Skopje, 
Macedonia from 2008 till 2016. The investigated 
group consisted of 90 hematologic patients – 30 
patients diagnosed with acute myeloid leukaemia 
(AML), 30 with lymphoma and 30 with multiple 
myeloma (MM). The study was approved by the 
Ethical Committee for Biomedical Research at 
Medical Faculty in Skopje. All subjects in the study 
gave their written consent for performing the research, 
mobilising strategy, apheresis collection of 
hematopoietic stem cells from peripheral blood, 
cryopreservation and transplantation (according to 
Recommendations of WMA Revision of Declaration of 
Helsinki). Mobilisation of HSC is performed with the 
granulocyte colony-stimulating factor (G-CSF) 10 
µcg/kg/day (as a single mobilising strategy) or in a 
combination of G-CSF + chemotherapy depending on 
diagnosis and disease status. The collection of HSC 
was performed by the apheresis procedure with the 
cellular separator COBE Spectra Version 6.1 
(TerumoBCT) in the Institute for Transfusion Medicine 
of RM, processing 2-2.5 total blood volumes [9]. The 
minimum number of HSC to be collected was ≥ 
2x10
8
/kg MNC and ≥ 2x10
6
/kg CD34+ cells. 
Cryopreservation and transplantation of HSC were 
performed at the University Clinic of Hematology. 
Irradiated and filtered blood products were given to 
maintain the haemoglobin level above 8 g/dl and the 
platelet count above 10x10
9
/l [21, 22]. The quality of 
hematopoietic stem cell grafts collected in our study 
was determined through their clinical efficiency in 
hematopoietic recovery after autologous 
transplantation. The number of CD34+ cells in the 
graft [23], the number of mononuclear cells (MNC) in 
the graft and the time to neutrophil and platelet 
engraftment were determined at the University Clinic 
of Hematology. Neutrophil engraftment was defined 
as the first of the three consecutive days post-
transplant where absolute neutrophil count reached > 
0.5x10
9
/l and platelet count > 20x10
9
/l, unsupported 
by transfusion and G-CSF more than five days from 
the first increase in the investigated parameters. 
 
Statistical analysis 
Statistical analysis was done in the statistical 
program Statistica 7.1 and SPSS 17.0. The following 
methods were used in this study: the percentage of 
structure (%) was determined in series with attributive 
marks; descriptive statistics (Mean ± Std.Dev., 
Minimum, Maximum, Median) was used in series with 
numerical marks; differences between the autologous 
subgroups of patients (AML, lymphoma and MM) in 
the parameters with attributive and numerical marks 
were tested with Analysis of Variance ANOVA test; 
the influence of possible predictive factors on 
hematopoietic recovery was determined by the 
multiple regression analysis. The accepted level of 
significance was p < 0.05. 
 
 
Results 
 
Characteristics of patients 
Characteristics of autologous transplanted 
patients with AML, lymphoma and MM are shown in 
Table 1. 
Table 1: Clinical characteristics of autologous transplanted 
patients with AML, lymphoma and MM 
Patients characteristics AML patients 
Number% 
Lymphoma patients 
Number% 
MM patients 
Number% 
Sex       
Men 17 56.7 20 66.7 19 63.3 
Women 13 43.3 10 33.3 11 36.7 
Age mean,std.dev,range) 44.5±13.7 (18-65) 37.6±12.0 (18-57) 53.1±7.8 (39-65) 
< 20 years 1 3.3 2 6.7 / / 
20-29 5 16.7 6 20.0 / / 
30-39 4 13.3 9 30.0 2 6.7 
40-49 6 20.0 7 23.3 8 26.7 
50-59 12 40.0 6 20.0 13 43.3 
>=60 2 6.7 / / 7 23.3 
Disease stage       
CR 30 100.0 6 20.0 10 33.3 
PR / / 6 20.0 17 56.7 
Relapse / / 18 60.0 3 10.0 
Chemotherapy cycles       
0       
1-4 28 93.3 1 3.3 16 53.3 
5-8 2 6.7 11 36.7 8 26.7 
9-12   10 33.3 3 10.0 
13-16   5 16.7 2 6.7 
≥ 17   3 10.0 1 3.3 
Time  from  diagnosis  to 
harvesting (months) 
4.8±1.9  
(range 1-11) 
33.2±41.1  
(range 5-148) 
12.5±15.2  
(range 2-79) 
Time  from  diagnosis  to 
HSCT 
5.8±1.8  
(range3-12) 
34.5±41.4  
(range 5-150) 
12.8±15.2  
(range 2-79) 
AML= acute myeloid leukaemia; MM = multiple myeloma; CR = complete remission; PR = 
partial remission; HSCT = hematopoietic stem cell transplantation. 
 
 
Number of transplanted peripheral blood 
hematopoietic stem cells 
The mean number of transplanted MNC and 
CD34+ cells in AML patients was 2.86±1.18 (range 
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0.9-5.8) and 2.62 ± 1.04 (range 0.9-5.5) respectively. 
The mean number of transplanted MNC and CD34+ 
cells in lymphoma patients was 3.18 ± 1.07 (range 
0.8-5.6) and 2.99 ± 0.94 (range 0.7-5.0) respectively. 
The mean number of transplanted MNC and 
CD34+ cells in MM patients was 3.23 ± 1.16 (range 
1.0-6.2) and 2.95 ± 1.18 (range 0.9-5.9) respectively. 
There was not statistically significant difference in the 
number of transplanted MNC and CD34+ cells between 
the autologous patients with AML, lymphoma and MM 
for p > 0.05 (F = 0.785031, p = 0.459309; F = 
1.059888; p = 0.350925). 
 
Engraftment 
Neutrophil engraftment (ANC > 0.5x10
9
/l) 
occurred mean on day 12.8 ± 3.2 (median 12) in 
AML patients (range 7-22); mean on day 12.1 ± 4.8 
(median 11) in lymphoma patients (range 7-25) and 
12.2 ± 2.7 (median 11) with range 8-19 in MM patients 
(Table 2). There was not statistically significant 
difference in the neutrophil engraftment time between 
AML, lymphoma and MM patients for p > 0.05 (p = 
0.787076). 
Table 2: Neutrophil engraftment (ANC > 0.5х10
9
/l) and platelet 
engraftment (Plt > 20x10
9
/l) in autologous transplanted patients 
with AML, lymphoma and MM 
ANC >0.5х10
9
/l Mean Median Minimum Maximum Std.Dev 
AML patients 12.8 12.0 7.0 22.0 3.15 
Lymphoma patients 12.1 11.0 7.0 25.0 4.80 
MM patients 12.2 11.0 8.0 19.0 2.74 
Plt >20х10
9
/l Mean Median Minimum Maximum Std.Dev 
AML patients 15.8 14.5 7.0 29.0 5.73 
Lymphoma patients 15.3 13.0 8.0 38.0 7.45 
MM patients 14.2 12.5 7.0 32.0 4.97 
ANC = absolute neutrophil count; Plt = platelets; N = number; Std. Dev.= standard 
deviation. 
 
Platelet engraftment (Plt > 20x10
9
/l) occurred 
mean on day 15.8 ± 5.7 (median 14.5) in AML patients 
(range 7-29); mean on day 15.3 ± 7.5 (median 13) in 
lymphoma patients (range 8-38) and 14.2 ± 5.0 
(median 12.5) with range 7-32 in MM patients (Table 
3). There was not statistically significant difference in 
the platelet engraftment time between AML, 
lymphoma and MM patients for > 0.05 (p = 0.588418). 
Table 3: Transfusion support in autologous transplanted 
patients with AML, lymphoma and MM 
Transfusion support 
AML patients 
Number (%) Mean Minimum Maximum Std. Dev. 
Erythrocytes  20 (66.7%) 2.95 1 6 1.61 
Random donor platelets 30 (100%) 35.10 12 93 19.40 
Single donor platelets 5 (16.7%) 2.00 1 5 1.73 
Fresh frozen plasma  28 (93.3%) 4.82 1 8 1.81 
Lymphoma patients Number (%) Mean Minimum Maximum Std. Dev. 
Erythrocytes  25 (83.3%) 3.52 2 12 2.30 
Random donor platelets 30 (100%) 24.23 3 108 21.10 
Single donor platelets 4 (13.3%) 1.00 1 1 0.00 
Fresh frozen plasma 30 (100%) 5.63 2 9 1.69 
MM patients Number / % Mean Minimum Maximum Std. Dev. 
Erythrocytes  18 (60%) 2.28 1 4 0.83 
Random donor platelets 27 (90%) 27.33 3 140 26.96 
Single donor platelets 3 (10%) 1.00 1 1 0.00 
Fresh frozen plasma 28 (93.3%) 2.89 1 32 5.75 
Note: 4-6 random donor platelet units make one adult therapeutic dose (ATD); one single 
donor platelet unit (apheresis platelet unit) is one ATD. 
 
Transfusion support with erythrocytes, 
random-donor platelets, single-donor platelets and 
fresh frozen plasma in autologous transplanted AML, 
lymphoma and MM patients is shown in Table 3. 
The biggest consumers of erythrocyte 
transfusions were lymphoma patients, the biggest 
consumers of platelet transfusions were AML patients 
and the biggest consumers of FFP were lymphoma 
patients. MM patients received less transfusion than 
the other two subgroups (AML and lymphoma 
patients). 
 
Multiple regression analysis 
The relationship between the neutrophil 
engraftment (ANC > 0.5x10
9
/l) in autologous 
transplanted patients with AML (dependent variable) 
and investigated possible predictive variables of 
interest was investigated with the multiple regression 
analysis.  
Table 4: Multiple regression analysis of neutrophil engraftment  
(ANC > 0.5x10
9
/l) in autologous transplanted patients with AML 
INDEPENDENT VARIABLES 
R = 0.871          R
2
 = 0.758 
F = 2.339        P = 0.025983 
Beta t – test p – level 
Age 0.017334 0.10645 0.916734 
Sex 0.552950 2.81100 0.013877* 
Mobilization  strategy -0.191639 -0.54733 0.592769 
Beginning of harvesting 0.345068 0.92407 0.371101 
Therapy regimen -0.304382 -1.23559 0.236943 
Chemotherapy cycles -0.052788 -0.24660 0.808796 
Comorbidity 0.076792 0.28509 0.779749 
Time from diagnosis to harvesting 0.375763 1.02715 0.321772 
Time from diagnosis to HSCT  -0.749913 -1.74343 0.103167 
Number of transplanted MNC 0.707462 2.74263 0.015873* 
Number of transplanted CD34+ cells 0.779065 3.07735 0.008193* 
Transfusion of Erythrocytes -0.020631 -0.12694 0.900792 
Transfusion of Platelets (RD)  0.552950 3.31236 0.005134* 
Transfusion of Platelets (SD) -0.315388 -1.76382 0.099562 
Transfusion of FFP  0.188833 0.99061 0.338688 
*statistically significant, ANC-absolute neutrophil count, HSCT-hematopoietic stem cell 
transplantation, MNC-mononuclear cells, RD-random-donor, SD-single-donor, FFP-fresh 
frozen plasma. 
 
The analysis showed that the coefficient of 
multiple correlations (R) was 0.871, the coefficient of 
determination (R
2
) was 0.758 and it showed that all 
independent variables together influence the 
variability of neutrophil engraftment in this group of 
patients with 75.8%, while 24.2% were influenced by 
other factors. The significance of the coefficient of 
multiple correlations (R) tested by F-distribution 
showed that the influence of possible predictive 
variables on neutrophil engraftment in autologous 
transplanted patients with AML is statistically 
significant for p = 0.025983. The analysis of 
independent variables showed that sex (Beta = 
0.552950, p = 0.013877), number of transplanted 
MNC (Beta = 0.707462, p = 0.015873), number of 
transplanted CD34+ cells (Beta = 0.779065, p = 
0.008193) and transfusion support with random donor 
platelets (Beta = 0.552950, p = 0.005134) had a 
significant influence on neutrophil engraftment in 
autologous transplanted patients with AML as 
presented in Table 4. 
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The relationship between the platelet 
engraftment (Plt > 20x10
9
/l) in autologous 
transplanted patients with AML (dependent variable) 
and investigated possible predictive variables of 
interest was investigated with the multiple regression 
analysis. The analysis showed that the coefficient of 
multiple correlations (R) was 0.880, the coefficient of 
determination (R
2
) was 0.775 and it showed that all 
independent variables together influence the 
variability of neutrophil engraftment in this group of 
patients with 77.5%, while other factors influenced 
22.5%. 
The significance of the coefficient of multiple 
correlations (R) tested by F-distribution showed that 
the influence of possible predictive variables on 
platelet engraftment in autologous transplanted 
patients with AML is statistically significant for p = 
0.017603. The analysis of independent variables 
showed that transfusion support with random-donor 
platelets had a significant influence on platelet 
engraftment in autologous transplanted patients with 
AML (Beta = 0.403, p = 0.03747). The influence of 
other predictive factors of interest was not statistically 
significant in this investigated group. 
Table 5: Multiple regression analysis of neutrophil engraftment 
(ANC > 0.5x10
9
/l) in autologous transplanted patients with 
lymphoma  
INDEPENDENT VARIABLES 
R = 0.906          R
2
 = 0.921 
F = 10.972        P = 0.000028 
Beta t - test p – level 
Age -0.50071 -4.57874 0.000429* 
Sex 0.30710 2.60319 0.020848* 
Mobilization strategy -1.02503 -3.49451 0.003574* 
Beginning of harvesting 0.40853 1.60416 0.130994 
Therapy regimen 0.03980 0.40630 0.690666 
Chemotherapy cycles -0.16572 -1.15800 0.266237 
Comorbidity 0.07835 0.66858 0.514640 
Time from diagnosis to harvesting -3.81958 -1.26518 0.226462 
Time from diagnosis to HSCT  4.39536 1.45727 0.167105 
Number of transplanted MNC 0.41135 2.87015 0.012349* 
Number of transplanted CD34+ cells 0.27615 1.83993 0.087074 
Transfusion of Erythrocytes 0.16855 1.82848 0.088859 
Transfusion of Platelets (RD)  0.09061 0.71402 0.486949 
Transfusion of Platelets (SD) 0.10904 1.01845 0.325742 
Transfusion of FFP  0.09635 0.92769 0.369287 
*Statistically significant, ANC-absolute neutrophil count, HSCT-hematopoietic stem cell 
transplantation, MNC-mononuclear cells, RD-random-donor, SD-single-donor, FFP-fresh 
frozen plasma. 
 
The relationship between the neutrophil 
engraftment (ANC > 0.5x10
9
/l) in autologous 
transplanted patients with lymphoma (dependent 
variable) and investigated possible predictive 
variables of interest was investigated with the multiple 
regression analysis. The analysis showed that the 
coefficient of multiple correlations (R) was 0.960, the 
coefficient of determination (R
2
) was 0.921 and it 
showed that all independent variables together 
influence the variability of neutrophil engraftment in 
this group of patients with 92.1%, while other factors 
influenced 7.9%. The significance of the coefficient of 
multiple correlations (R) tested by F-distribution 
showed that the influence of possible predictive 
variables on neutrophil engraftment in autologous 
transplanted patients with lymphoma is statistically 
significant for p = 0.000028. The analysis of 
independent variables showed that age (Beta =       -
0.50071, p = 0.000429), sex (Beta = 0.30710, p = 
0.020848), mobilizing strategy (Beta = -1.02503, p = 
0.003574) and number of transplanted MNC (Beta = 
0.41135, p = 0.012349) had a significant influence on 
neutrophil engraftment in autologous transplanted 
patients with lymphoma as presented in Table 5. 
The relationship between the platelet 
engraftment (Plt > 20x10
9
/l) in autologous 
transplanted patients with lymphoma (dependent 
variable) and investigated possible predictive 
variables of interest was investigated with the multiple 
regression analysis. The analysis showed that the 
coefficient of multiple correlations (R) was 0.913, the 
coefficient of determination (R
2
) was 0.839 and it 
showed that all independent variables together 
influence the variability of neutrophil engraftment in 
this group of patients with 83.9%, while other factors 
influenced 16.1%. The significance of the coefficient 
of multiple correlations (R) tested by F-distribution 
showed that the influence of possible predictive 
variables on platelet engraftment in autologous 
transplanted patients with lymphoma is statistically 
significant for p = 0.002622. The analysis of 
independent variables showed that age (Beta = 0.470, 
p = 0.009697), sex (Beta = 0.333, p = 0.069099), time 
from diagnosis to harvesting (Beta = 11.261, p = 
0.021012) and time from diagnosis to HSCT (Beta = 
11.408, p = 0.019575) had a significant influence on 
platelet engraftment in autologous transplanted 
patients with lymphoma. 
The relationship between the neutrophil 
engraftment (ANC >0.5x10
9
/l) in autologous 
transplanted patients with MM (dependent variable) 
and investigated possible predictive variables of 
interest was investigated with the multiple regression 
analysis. The analysis showed that the coefficient of 
multiple correlations (R) was 0.833, the coefficient of 
determination (R
2
) was 0.694 and it showed that all 
independent variables together influence the 
variability of neutrophil engraftment in this group of 
patients with 69.4%, while other factors influenced 
30.6%. The significance of the coefficient of multiple 
correlations (R) tested by F-distribution showed that 
the influence of possible predictive variables on 
neutrophil engraftment in autologous transplanted 
patients with MM was not statistically significant for p 
= 0.084509. The analysis of independent variables 
showed that the influence of possible predictive 
variables of interest is not statistically significant in this 
investigated group. 
The relationship between the platelet 
engraftment (Plt > 20x10
9
/L) in autologous 
transplanted patients with MM (dependent variable) 
and investigated possible predictive variables of 
interest was investigated with the multiple regression 
analysis. The analysis showed that the coefficient of 
multiple correlations (R) was 0.908, the coefficient of 
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determination (R
2
) was 0.824 and it showed that all 
independent variables together influence the 
variability of platelet engraftment in this group of 
patients with 82.4%, while other factors influenced 
17.6%.  
Table 6: Multiple regression analysis of platelet engraftment 
(Plt > 20x10
9
/l) in autologous transplanted patients with MM 
INDEPENDENT VARIABLES R = 0.908          R
2
 = 0.824 
F = 4.366        P = 0.004381 
Beta t - test p – level 
Age 0.10858 0.50699 0.620055 
Sex -0.08515 -0.46229 0.650979 
Mobilization strategy -0.39208 -0.66121 0.519213 
Beginning of harvesting 0.35460 0.59844 0.559106 
Therapy regimen -0.25366 -1.17937 0.257904 
Chemotherapy cycles 0.24995 1.59500 0.133031 
Comorbidity 0.38512 1.56811 0.139176 
Time from diagnosis to harvesting 6.24264 1.08700 0.295400 
Time from diagnosis to HSCT  -6.59594 -1.13894 0.273844 
Number of transplanted MNC 0.46029 1.75179 0.101675 
Number of transplanted CD34+ cells 0.16634 0.77478 0.451358 
Transfusion of Erythrocytes 0.00532 0.02629 0.979399 
Transfusion of Platelets (RD)  0.73295 3.93110 0.001507* 
Transfusion of Platelets (SD) -0.13368 -0.68497 0.504544 
Transfusion of FFP  0.07233 0.36000 0.724219 
*statistically significant, Plt-platelets, HSCT-hematopoietic stem cell transplantation, MNC-
mononuclear cells, RD-random-donor, SD-single-donor, FFP-fresh frozen plasma. 
 
The significance of the coefficient of multiple 
correlations (R) tested by F-distribution showed that 
the influence of possible predictive variables on 
platelet engraftment in autologous transplanted 
patients with MM is statistically significant for p = 
0.004381. The analysis of independent variables 
showed that transfusion support with random donor 
platelets had a significant influence on platelet 
engraftment in autologous transplanted patients with 
MM (Beta = 0.73295; p = 0.001507). The influence of 
other predictive factors of interest was not statistically 
significant in this investigated group (Table 6). 
 
 
Discussion 
 
Our study showed that there was not 
statistically significant difference in the neutrophil and 
platelet engraftment time between the autologous 
transplanted patients with AML, lymphoma and MM. 
On the other side, neutrophil and platelet engraftment 
occurred more rapidly in patients with multiple 
myeloma and lymphoma when compared to patients 
with leukaemia, myelodysplastic syndrome and 
aplastic anaemia in the study of Goncalves TL et al., 
suggesting that residual leukaemia in the patient may 
contribute to delayed engraftment. Other factors, 
included the drug used in the conditioning regimen, 
where Cyclophosphamide + BCNU + VP-16, 
Melphalan and Fludarabine + Cyclophosphamide 
showed faster engraftment. Age 50–59 years 
demonstrated faster engraftment. Sex did not 
influence neutrophil and platelet recovery in this study 
[7]. Quite the opposite, sex had a significant influence 
on the neutrophil engraftment in autologous 
transplanted patients with AML and lymphoma in our 
study, and on platelet engraftment in autologous 
transplanted patients with lymphoma. Factors affecting 
neutrophil recovery in the not- myeloid malignancy 
(NNM) group of patients in the study of Carral A et al. 
were the CD34+ cell number and the CFU-GM dose 
infused, whereas, for platelet recovery, previous 
chemotherapy remained significant. In the AML group, 
hematopoietic recovery was slower than in the NMM 
group (12 vs. 14 days; p = 0.01). The CD34+ cell dose 
administered and patient’s age were the only factors 
significantly affecting the speed of neutrophil recovery, 
while the CD34+ cell dose significantly influenced 
platelet recovery in these patients. In the NMM group, 
the most discriminating cut-off values for a rapid 
neutrophil and platelet recovery were 1.5x10
6 and 
2.5x10
6 
CD34+ cells/kg, respectively, and for AML 
patients these figures were 1.5x10
6 and 4x10
6 CD34+ 
cells/kg, respectively [13]. History of pre-transplant 
radiotherapy, type of growth factor used for HSC 
mobilisation and the number of infused CD34+ cells 
for neutrophil engraftment and history of pre-
transplant radiotherapy for platelet engraftment were 
independent variables that influenced hematopoietic 
recovery in autologous transplanted patients in the 
study of Turk HM at al. [20]. Olivieri A et al. [24] found 
out that the number of transplanted CD34+ cells 
>5x10
6
/kg in autologous patients is optimal for rapid 
neutrophil and platelet engraftment. Neutrophil 
engraftment occurred on day 11 (range 8-15) and 
platelet engraftment on day 12 (range 8-24). Patients 
who received 5.0-7.8x10
6
/kg CD34+ cells had shorter 
neutropenia, needed fewer platelet transfusions and 
spent less time in the hospital than those who 
received fewer cells, while patients transplanted with a 
larger number of cells did not have any advantages. 
Neutrophil and platelet engraftment was significantly 
prolonged when transplanted <2x10
6
/kg CD34+ cells 
in autologous patients (12 vs. 10 days, p = 0.014, 
respectively 16 vs. 13 days p = 0.0001) in the study of 
Villalon L et al. [25]. Platelet engraftment was affected 
with alkylating agents and refractory disease. 
Neutrophil engraftment was longer in patients with 
chronic myeloid leukaemia, acute myeloid leukaemia 
and refractory disease. In patients who received more 
than >2x10
6
/kg CD34+ cells, Cox model did not 
identify prognostic factor for hematopoietic recovery. 
Although mobilising strategy and disease status 
influenced not only the number of collected HSC but 
the engraftment kinetics as well, this study showed 
that the number of infused CD34+ cells is the main 
predictor of hematopoietic recovery. Possible 
predictive factors that could influence neutrophil and 
platelet engraftment: sex, age, diagnosis, number of 
CD34+ cells infused, time from diagnosis to HSCT, 
number of apheresis, conditioning, and G-CSF 
support, investigated, in the study of Ergene U et al. 
revealed that the number of CD34+ cells >10x10
6
/kg, 
time from diagnosis to HSCT is longer than a year and 
conditioning with BEAM were statistically significant for 
neutrophil engraftment in the univariate analysis. In 
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the multivariate analysis, none of these factors was 
significant. The number of CD34+ cells >7x10
6
/kg, 
diagnosis of myeloma multiplex, time from 
diagnosis to HSCT, beginning of G-CSF (>2 days) 
were statistically significant in the univariate analysis 
for platelet engraftment, while in the multivariate 
analysis only the number of CD34+ cells was 
significant [26]. Similarly, the number of transplanted 
MNC and CD34+ cells significantly influenced 
neutrophil recovery in autologous transplanted 
patients with AML in our study. Mobilisation strategy 
significantly influenced neutrophil recovery in 
autologous transplanted patients with lymphoma in 
our study, while age, time from diagnosis to 
harvesting and time from diagnosis to HSCT 
significantly influenced platelet recovery in the same 
group of patients. On the contrary, another study [27] 
showed that larger number of infused CD34+ cells and 
fewer days for collection of HSC (minimum 2x10
6
/kg 
CD34+ cells) did not provide faster engraftment. Thus 
mobilisation and harvesting of HSC should not be 
used as independent factors to predict engraftment. In 
the study of Alshemmari SH et al. [28], the number of 
autologous transplanted CD34+ cells was the most 
significant parameter of platelet engraftment. 
Furthermore, the number of transplanted CD34+ 
cells did not significantly affect neutrophil engraftment. 
The median number of transplanted CD34+ was 
7x10
6
/kg (0.38-15), neutrophil engraftment occurred 
on day 12 [10-15] and platelet on day 11 [6-33]. Other 
investigated factors didn’t affect the engraftment 
kinetics of the investigated group. Tricot G et al. 
pointed out in their study that prudent use of stem cell-
damaging agents, such as Melphalan, is 
recommended in patients with refractory multiple 
myeloma who might be candidates for autologous 
transplantation. Authors suggested that peripheral 
blood stem cells should be collected early after 
diagnosis. Fast recovery of platelets to greater than 
50 x 10
9
/l within 14 days after high-dose 
cyclophosphamide and < or = 12 months of prior 
chemotherapy were the best predictors of early 
engraftment [29]. Yuan S et al. [30] investigated the 
post- transplant outcomes of 105 adult patients with 
lymphoma and compared the post-transplant 
outcomes of 21 patients who received Plerixafor in 
addition to G-CSF ± chemotherapy, because of poor 
mobilisation, with those of 84 patients who mobilised 
well without Plerixafor. Despite collecting significantly 
lower CD34+ cell doses (median of 3.41 vs. 
6.05×10
6
/kg, p < 0.0001) than control patients and 
requiring more collection days, Plerixafor-mobilized 
patients showed comparable early engraftment 
characteristics except for slightly delayed neutrophil 
engraftment (median 11 vs. 10 days, p = 0.002) 
and lower median neutrophil counts (2.1 vs. 
2.6 × 10
9
/l, p = 0.04) at one month after transplant. The 
most important factor influencing platelet recovery of 
autologous transplanted patients with multiple 
myeloma and lymphoma was a diagnosis, followed by 
the amount of reinfused CD34+ cells. Blood group O+ 
had the fastest platelet recovery, whereas blood group 
A harvested the highest cell amounts in the study of 
Ungerstedt JS et al. [31]. Recipients of transplanted 
hematopoietic stem cells often require a significant 
amount of transfusions, especially the ones with 
delayed hematopoietic recovery and platelet 
alloimmunization. Evaluation of clinical factors 
affecting transplant engraftment and transfusion 
utilisation in the study of Liesfeld J et al. found out that 
graft type, donor type and the conditioning regimen 
intensity significantly affected both the neutrophil 
engraftment time and the platelet engraftment time. 
Transplanted patients required an average of 6.2 red 
cell units, and 7.9 platelet transfusions in the first 100 
days. Female gender, unrelated donor transplant, 
leukaemia, high conditioning regimen intensity and 
receiving TBI were associated with the higher need 
for RBC unit transfusion. The number of transfusions 
administered was not affected by age, CD34+ cell 
number infused or graft type. Among autologous 
transplanted patients, 5% required neither red blood 
cells, nor platelet transfusions, as well as some 
patients who received reduced-intensity conditioning 
[32]. Among the autologous transplanted patients in 
our study, there was only one patient (1.1%) who 
didn’t receive any transfusion. The biggest consumers 
of erythrocyte transfusions in our study were 
lymphoma patients (83.3%), with average of 3.5 units 
(range 2-12), The biggest consumers of platelet 
transfusions were AML patients (100%) with average 
of 35.1 random-donor platelet units equal to ~ 7 adult 
therapeutic doses [22], and the biggest consumers of 
FFP were lymphoma patients (100%) with average of 
5.6 units till hematopoietic recovery. MM patients 
received fewer transfusions than the other two 
subgroups. The need for red cell and platelet 
transfusion may vary significantly depending on the 
type of transplantation and underlying disease. There 
were 30 (11.6%) patients who did not require platelet 
support, 52 (20.0%) did not require RBC support and 
13 (5.0%) had no transfusions of either RBCs or 
platelets in the investigated group of 259 autologous 
transplanted patients, in the study of Gamguly S et al. 
[33]. Transfusion of blood products is an expensive 
but integral part of HSCT. 
Random donor platelet transfusion was one of 
the factors that had the biggest influence on the 
neutrophil recovery in autologous transplanted 
patients with AML, in our study, as well as the platelet 
recovery in autologous transplanted patients with AML 
and MM, which implies that transfusion support with 
blood component is essential for effective HSCT and 
fast hematopoietic recovery. 
Rapid and durable hematopoietic recovery 
following HSCT is a prerequisite for successful 
hematopoietic stem cell transplantation. Additional 
studies are necessary to better understanding of 
engraftment kinetic to minimise the use of 
transfusions and potential complications related to 
HSCT, as well as to reduce the expenses associated 
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to HSCT and improve the safety of hematopoietic 
stem cell transplantation. 
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